The GABAB antagonist, CGP 35348, antagonizes the effects of baclofen, γ-butyrolactone and HA 966 on rat striatal dopamine synthesis

@article{Waldmeier1991TheGA,
  title={The GABAB antagonist, CGP 35348, antagonizes the effects of baclofen, γ-butyrolactone and HA 966 on rat striatal dopamine synthesis},
  author={Peter C. Waldmeier},
  journal={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={1991},
  volume={343},
  pages={173-178}
}
The effects of the new GABAB antagonist, CGP 35348 (3-aminopropane-diethoxymethylphosphinic acid), on rat striatal dopamine synthesis and the increases thereof, caused by (−)-baclofen, γ-butyrolactone (GBL), and HA 966 (3-amino-l-hydroxypyrrolid-2-one), were investigated. CGP 35348 did not alter dopamine synthesis on its own up to the highest dose tested (500 mg/kg i.p.). However, it antagonized the increase elicited by 50 mg/kg s. c. (−)-baclofen at doses above 100 mg/kg i. p.; at 500 mg/kg i… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

Biochemistry , electrophysiology and pharmacology of a new GABAB antagonist

  • H Bittiger, K Hauser, +7 authors A Vassout
  • 1990

Vassout A (1990) Biochemistry, electrophysiology and pharmacology of a new GABAB antagonist

  • H Bittiger, W Fr6stl, +7 authors H Van Riezen
  • Bowery NG,
  • 1990
3 Excerpts

Weak impact of GABA uptake inhibition on nigrostriatal dopamine function

  • PC Waldmeier
  • Biogenic Amines
  • 1990

Similar Papers

Loading similar papers…